Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trialPaolo F. Caimi, Carmelo Carlo‐Stella, Weiyun Z. Ai et al.|The Lancet Oncology|2021Cited by 428
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell LymphomaPaolo F. Caimi, Carmelo Carlo‐Stella, Melhem Solh et al.|Blood|2020Cited by 17
Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin LymphomaBrian Hess, Joseph Boni, William Townsend et al.|The AAPS Journal|2021Cited by 13
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAPier Luigi Zinzani, M. Hamadani, Paolo F. Caimi et al.|Hematological Oncology|2021Cited by 8
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 studyJuan Pablo Alderuccio, Paolo F. Caimi, Weiyun Z. Ai et al.|Blood Advances|2022Cited by 6